Skip to content
drillr.ai
Sign up

KPTI

Karyopharm Therapeutics Inc.

NASDAQ · Healthcare · Biotechnology · US

$0.09
−0.34%
Ask drillr

  • Nov 3, 2026, 11:14 UTC

    Karyopharm Therapeutics entered into a $110 million super-priority senior secured debtor-in-possession term loan facility, including up to $55 million of new-money loans and second-out roll-up loans, subject to court approval.

  • Nov 2, 2026, 13:13 UTC

    Karyopharm Therapeutics Inc. filed for bankruptcy.

    Source:

  • Nov 2, 2026, 12:10 UTC

    Karyopharm Therapeutics entered into a restructuring support agreement providing for a merger with Ayrmid Ltd. and a court-supervised sale process in which Ayrmid will serve as lead bidder.

    Source:

  • Sep 23, 2026, 23:59 UTC

    Karyopharm pushed off a debt payment, buying an extra month to negotiate with creditors or pursue a deal.

    Source:

  • Aug 31, 2026, 11:30 UTC

    Karyopharm Therapeutics submitted a supplemental New Drug Application to the U.S. FDA seeking Accelerated Approval for XPOVIO (selinexor) in combination with ruxolitinib for patients with myelofibrosis.

    Source:

  • Aug 13, 2026, 13:51 UTC

    Karyopharm Therapeutics reported a Q2 2026 loss of $2.32 per share, missing the Zacks Consensus Estimate of a loss of $1.53, and compared to a loss of $4.32 per share a year ago.

    Source:

  • Jul 30, 2026, 20:06 UTC

    Karyopharm Therapeutics plans to submit a supplemental New Drug Application to the FDA in August 2026 for accelerated approval of selinexor plus ruxolitinib for myelofibrosis.

    Source:

  • Jul 30, 2026, 20:05 UTC

    Karyopharm Therapeutics announced topline results from its Phase 3 XPORT-EC-042 trial evaluating selinexor in endometrial cancer, which did not meet the primary endpoint.

    Source: